United Kingdom

Austria's VALANX Biotech secures €2.3M for Drug Development and Diagnostics
VALANX Biotech, a synthetic biology company headquartered in Austria, has revealed the successful acquisition of €2.3 million in a growth funding round.

The best Articles in our Network

Previous
Next